Page 4 - Global External News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Inventiva and Hepalys Pharma, Inc announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

Inventiva and Hepalys Pharma, Inc announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaNew yorkUnited statesSan franciscoSouth koreanSouth koreansCatalys pacificHepalys pharmaAude lepreuxNonliver comorbiditiesPascaline clercExchange commission onMitsubishi ufjInnovation fundHepalys pharma inc weGlobal external affairs

INVENTIVA: Inventiva and Hepalys Pharma, Inc announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

INVENTIVA: Inventiva and Hepalys Pharma, Inc announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesNew yorkSan franciscoBaden wübergSouth koreansSouth koreanNonliver comorbiditiesPascaline clercAude lepreuxCatalys pacificHepalys pharmaExchange commission onHepalys pharma incInnovation fundMitsubishi ufj

Inventiva and Hepalys Pharma, Inc announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea -September 20, 2023 at 04:01 pm EDT

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million.

United statesNew yorkSan franciscoSouth koreaSouth koreansSouth koreanAude lepreuxCatalys pacificNonliver comorbiditiesHepalys pharmaPascaline clercHepalys pharma incGlobal external affairsExchange commission onBrunswick groupMitsubishi ufj

Inventiva announces a financing of approximately €35 7 million from new and existing investors, consisting of a €30 6 million reserved capital increase and a €5 1 million issuance of royalty certificates

Daix , Long Island City , August 31, 2023 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with.

France generalUnited kingdomNew yorkUnited statesAude lepreuxPascaline clercPierre broquaDavid nikodemEuropean investment bankEuropean parliamentEnterprise associatesPatricial bankEuropean unionFinancial servicesGlobal external affairsQatar holding

INVENTIVA: Inventiva announces a financing of approximately €35 7 million from new and existing investors, consisting of a €30 6 million reserved capital increase and a €5 1 million issuance of royalty certificates

INVENTIVA: Inventiva announces a financing of approximately €35 7 million from new and existing investors, consisting of a €30 6 million reserved capital increase and a €5 1 million issuance of royalty certificates
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesNew yorkFrance generalDavid nikodemPierre broquaPascaline clercAude lepreuxEuropean unionPatricial bankEuropean investment bankFinancial servicesBrunswick groupEuropean parliamentGlobal external affairsCompany board of directors